Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; sodium calcium edetate; trometamol; water for injections; sodium hydroxide - ultravist is indicated for all angiographic and urographic examinations and for contrast enhancement in computerised tomography.,ultravist 300 or 370 is indicated for use in contrast-enhanced mammography (cem) in adults, to visualise known or suspected lesions of the breast as an adjunct to mammography (with or without ultrasound).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 498.72 mg/ml - injection, solution - excipient ingredients: water for injections; trometamol; sodium calcium edetate; dilute hydrochloric acid; sodium hydroxide - indications: ultravist is indicted for all angiographic and urographic examinations and for contrast enhancements in computerised tomography. ultravist 240 is additionally indicated for lumbar myelography in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 498.72 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; water for injections; trometamol; sodium calcium edetate; sodium hydroxide - indications: ultravist is indicated for all angiographic and urographic examinations and for contrast enhancements in computerised tomography. ultravist 240 is additionally indicated for lumbar myelography in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 498.72 mg/ml - injection, solution - excipient ingredients: water for injections; trometamol; sodium calcium edetate; dilute hydrochloric acid; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerized tomography. indications as at 6th july 2001: ultravist is indicated for all angiographic and urographic examinations and for contrast enhancements in computerised tomography. ultravist 240 is additionally indicated for lumbar myelography in adults.

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - iopromide (unii: 712bac33mz) (iopromide - unii:712bac33mz) - ultravist® injection is an iodinated contrast agent indicated for: ultravist is indicated for: ultravist is indicated for: † specific concentrations and presentations of ultravist are recommended for each type of imaging procedure [see dosage and administration ( 2.2, 2.3, 2.4)]. there are no data on ultravist use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. iopromide crosses the placenta and reaches fetal tissues in small amounts (see data) . in animal reproduction studies, intravenous administration of iopromide to pregnant rats and rabbits during organogenesis at doses up to0.35 and 0.7 times, respectively, the maximum recommended human dose based on body surface area resulted in no relevant adverse developmental effects (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other advers

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iopromide 498.72 mg/ml equivalent to 240 mg iodine - solution for infusion - 240 mg/ml - active: iopromide 498.72 mg/ml equivalent to 240 mg iodine excipient: hydrochloric acid as 10% solution sodium calcium edetate, hydrate trometamol water for injection - for intravascular use and use in body cavities. contrast enhancement in computerised tomography (ct), arteriography and venography, intravenous/intra-arterial digital subtraction angiography (dsa), intravenous urography, use for ercp, arthrography and examination of other body cavities. ultravist 240: also for intrathecal use. ultravist 370: especially for angiocardiography. ultravist 300/370: not for intrathecal use.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iopromide 623 mg/ml equivalent to iodine 300 mg/ml - solution for infusion - 300 mg/ml - active: iopromide 623 mg/ml equivalent to iodine 300 mg/ml excipient: hydrochloric acid as 10% solution sodium calcium edetate trometamol water for injection - for intravascular use and use in body cavities. contrast enhancement in computerised tomography (ct), arteriography and venography, intravenous/intra-arterial digital subtraction angiography (dsa), intravenous urography, use for ercp, arthrography and examination of other body cavities. ultravist 240: also for intrathecal use. ultravist 370: especially for angiocardiography. ultravist 300/370: not for intrathecal use.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iopromide 769 mg/ml equivalent to iodine 370 mg/ml - solution for infusion - 370 mg/ml - active: iopromide 769 mg/ml equivalent to iodine 370 mg/ml excipient: hydrochloric acid sodium calcium edetate trometamol water for injection - for intravascular use and use in body cavities. contrast enhancement in computerised tomography (ct), arteriography and venography, intravenous/intra-arterial digital subtraction angiography (dsa), intravenous urography, use for ercp, arthrography and examination of other body cavities. ultravist 240: also for intrathecal use. ultravist 370: especially for angiocardiography. ultravist 300/370: not for intrathecal use.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection - excipient ingredients: trometamol; sodium calcium edetate; water for injections; dilute hydrochloric acid; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.